US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide ...

Wall Street’s major averages closed Friday's trading session higher, as both the S&P 500 (SP500) and Nasdaq Composite ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Amgen Inc. (NASDAQ: AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street’s reaction to the company’s latest data announcement regarding MariTide, ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...